Sections

Sort by
Previous Page Page 1 of 58 Next Page
  1. Research article

    Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer

    Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targe...

    Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward and Sarah L. Young

    Journal for ImmunoTherapy of Cancer 2017 5:69

    Published on: 15 August 2017

  2. Research article

    Tumor-derived exosomes induce CD8+ T cell suppressors

    The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous work demonstrated that a soluble factor from tumor cells is able ...

    Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero and Brian R. Gastman

    Journal for ImmunoTherapy of Cancer 2017 5:65

    Published on: 15 August 2017

  3. Research article

    Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

    Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to...

    Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj and William K. Oh

    Journal for ImmunoTherapy of Cancer 2017 5:67

    Published on: 15 August 2017

  4. Research article

    The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

    T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of M...

    Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart and Robert W. Wilkinson

    Journal for ImmunoTherapy of Cancer 2017 5:63

    Published on: 15 August 2017

  5. Position Article and Guidelines

    Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

    The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and dest...

    Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham…

    Journal for ImmunoTherapy of Cancer 2017 5:68

    Published on: 15 August 2017

  6. Research article

    Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy

    We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...

    Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif

    Journal for ImmunoTherapy of Cancer 2017 5:64

    Published on: 15 August 2017

  7. Case report

    Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

    Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1...

    Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott and Toni K. Choueiri

    Journal for ImmunoTherapy of Cancer 2017 5:66

    Published on: 15 August 2017

  8. Research article

    Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination

    Immunotherapies have demonstrated clinical benefit for many types of cancers, however many patients do not respond, and treatment-related adverse effects can be severe. Hence many efforts are underway to ident...

    Laura E. Johnson, Brian M. Olson and Douglas G. McNeel

    Journal for ImmunoTherapy of Cancer 2017 5:56

    Published on: 18 July 2017

  9. Review

    Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

    The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 ...

    Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries and Dominik Rüttinger

    Journal for ImmunoTherapy of Cancer 2017 5:53

    Published on: 18 July 2017

  10. Case report

    Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma

    The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopath...

    Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas and Stephane Dalle

    Journal for ImmunoTherapy of Cancer 2017 5:57

    Published on: 18 July 2017

  11. Case report

    Angiosarcoma treated successfully with anti-PD-1 therapy - a case report

    Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than 40%. These tumors can be found in all age groups, but are more common in older patient...

    Simran Sindhu, Lana H. Gimber, Lee Cranmer, Ali McBride and Andrew S. Kraft

    Journal for ImmunoTherapy of Cancer 2017 5:58

    Published on: 18 July 2017

  12. Case report

    Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes

    The tumor microenvironment often polarizes infiltrating macrophages towards a type 2, or M2 phenotype, that is characterized by expression of various cysteine-rich, scavenger receptors, including CD163. The pr...

    Michael C. Topf, Madalina Tuluc, Larry A. Harshyne and Adam Luginbuhl

    Journal for ImmunoTherapy of Cancer 2017 5:60

    Published on: 18 July 2017

  13. Research article

    GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory

    The expansion of antigen-specific CD8 T cells is important in generating an effective and long-lasting immune response to tumors and viruses. Glucocorticoid-induced tumor necrosis factor receptor family-relate...

    Nick M. Durham, Nick Holoweckyj, Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow and Scott H. Robbins

    Journal for ImmunoTherapy of Cancer 2017 5:47

    Published on: 20 June 2017

  14. Research article

    Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice

    Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy for patients with advanced cancers. However, identi...

    Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese and Bryon D. Johnson

    Journal for ImmunoTherapy of Cancer 2017 5:51

    Published on: 20 June 2017

  15. Review

    New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

    This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November...

    Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky Jr., Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey…

    Journal for ImmunoTherapy of Cancer 2017 5:50

    Published on: 20 June 2017

  16. Research article

    Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma

    Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce a...

    Anna Laurell, Maria Lönnemark, Einar Brekkan, Anders Magnusson, Anna Tolf, Anna Carin Wallgren, Bengt Andersson, Lars Adamson, Rolf Kiessling and Alex Karlsson-Parra

    Journal for ImmunoTherapy of Cancer 2017 5:52

    Published on: 20 June 2017

  17. Case report

    Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade

    Stimulation of the immune system by targeting the PD-1/PD-L1 pathway can result in activation of anti-tumor immunity. Besides its clinical benefit immune checkpoint therapy leads to significant immune-related ...

    Heinz Läubli, Jürgen Hench, Michal Stanczak, Ingmar Heijnen, Alexandros Papachristofilou, Stephan Frank, Alfred Zippelius and Frank Stenner-Liewen

    Journal for ImmunoTherapy of Cancer 2017 5:46

    Published on: 20 June 2017

  18. Case report

    Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

    Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically exclu...

    Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers and Hussein Tawbi

    Journal for ImmunoTherapy of Cancer 2017 5:45

    Published on: 20 June 2017

  19. Case report

    Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy

    We report the first case to our knowledge of a patient with relapsed/refractory classical hodgkin lymphoma and liver failure with encephalopathy along with human immunodeficiency virus/acquired immunodeficienc...

    Jose D. Sandoval-Sus, Francis Mogollon-Duffo, Ankita Patel, Nathan Visweshwar, Damian A. Laber, Richard Kim and Michael V. Jagal

    Journal for ImmunoTherapy of Cancer 2017 5:49

    Published on: 20 June 2017

  20. Erratum

    Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

    Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Journal for ImmunoTherapy of Cancer 2017 5:48

    Published on: 30 May 2017

    The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:39

Previous Page Page 1 of 58 Next Page
JITC logo

Advertisement